A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2017
At a glance
- Drugs BPX 201 (Primary) ; Rimiducid
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Sep 2017.